- Home
- ANNX vs ATNI Comparison
ANNX vs ATNI Comparison
Compare ANNX & ATNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- ATNI
- Stock Information
- Founded
- ANNX 2011
- ATNI 1987
- Country
- ANNX United States
- ATNI United States
- Employees
- ANNX N/A
- ATNI N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- ATNI Telecommunications Equipment
- Sector
- ANNX Health Care
- ATNI Telecommunications
- Exchange
- ANNX Nasdaq
- ATNI Nasdaq
- Market Cap
- ANNX 253.8M
- ATNI 254.3M
- IPO Year
- ANNX 2020
- ATNI 1991
- Fundamental
- Price
- ANNX $2.64
- ATNI $15.45
- Analyst Decision
- ANNX Strong Buy
- ATNI Strong Buy
- Analyst Count
- ANNX 5
- ATNI 1
- Target Price
- ANNX $13.00
- ATNI $30.00
- AVG Volume (30 Days)
- ANNX 1.6M
- ATNI 32.1K
- Earning Date
- ANNX 11-13-2025
- ATNI 10-28-2025
- Dividend Yield
- ANNX N/A
- ATNI 6.97%
- EPS Growth
- ANNX N/A
- ATNI N/A
- EPS
- ANNX N/A
- ATNI N/A
- Revenue
- ANNX N/A
- ATNI $719,593,000.00
- Revenue This Year
- ANNX N/A
- ATNI $1.60
- Revenue Next Year
- ANNX N/A
- ATNI $1.38
- P/E Ratio
- ANNX N/A
- ATNI N/A
- Revenue Growth
- ANNX N/A
- ATNI N/A
- 52 Week Low
- ANNX $1.29
- ATNI $13.76
- 52 Week High
- ANNX $7.85
- ATNI $33.72
- Technical
- Relative Strength Index (RSI)
- ANNX 62.43
- ATNI 44.67
- Support Level
- ANNX $2.32
- ATNI $15.22
- Resistance Level
- ANNX $2.70
- ATNI $17.01
- Average True Range (ATR)
- ANNX 0.16
- ATNI 0.97
- MACD
- ANNX 0.06
- ATNI -0.03
- Stochastic Oscillator
- ANNX 87.57
- ATNI 18.50
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.